Indeed, a phase II clinical trial testing the efficacy of the GLUT inhibitors Lopinavir and Ritonavir only produced a complete response to treatment in one recurrent high-grade glioma patient, while 79% experienced progression of the disease [48]. The gene discussed is SLC2A1; the disease is malignant glioma.